Cytokinetics Files 8-K on Financials
Ticker: CYTK · Form: 8-K · Filed: Aug 7, 2025 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K |
| Filed Date | Aug 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Cytokinetics dropped an 8-K on Aug 7th detailing their financial results. Check it out.
AI Summary
Cytokinetics, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 350 Oyster Point Boulevard, South San Francisco, California.
Why It Matters
This filing provides an update on Cytokinetics' financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any unusual or immediate risks.
Key Players & Entities
- Cytokinetics, Inc. (company) — Registrant
- August 07, 2025 (date) — Date of earliest event reported
- 350 Oyster Point Boulevard (location) — Principal Executive Offices Address
- South San Francisco, California (location) — Principal Executive Offices City and State
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported was on August 07, 2025.
What is Cytokinetics, Inc.'s principal executive office address?
The principal executive offices are located at 350 Oyster Point Boulevard, South San Francisco, California, 94080.
What is the company's fiscal year end?
The company's fiscal year end is December 31.
Under which section of the Securities Exchange Act is this report filed?
This Current Report is filed Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-08-07 16:01:47
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se
Filing Documents
- cytk-20250807.htm (8-K) — 41KB
- cytk-ex99_1.htm (EX-99.1) — 253KB
- img114956760_0.jpg (GRAPHIC) — 23KB
- 0000950170-25-104962.txt ( ) — 446KB
- cytk-20250807.xsd (EX-101.SCH) — 24KB
- cytk-20250807_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Cytokinetics, Incorporated announced its financial results for the second quarter ended June 30, 2025. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished under this Item 2.02 and under Exhibit 99.1 shall not be considered "filed" under the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, unless the Registrant expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release dated August 7, 2025 104 The cover page of this report has been formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: August 7, 2025 By: /s/ John O. Faurescu John O. Faurescu, Esq. Vice President, Associate General Counsel & Secretary